Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial.


Despite the prevalence of multisomatoform disorder (MSD), there are few controlled trials of its pharmacotherapy. The aim of this study was to compare the efficacy and safety of escitalopram (10-20 mg/day) with that of placebo in treating patients with MSD over a 12-week period. Fifty-one outpatients aged from 18 to 65 years, with multiple medically… (More)


  • Presentations referencing similar topics